Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has gone rise by 3.67 in comparison to its previous close of 17.97, however, the company has experienced a 5.85% increase in its stock price over the last five trading days. zacks.com reported 2024-12-09 that SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company’s lead pipeline drug.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
SMMT has 36-month beta value of -0.91. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SMMT is 103.50M, and currently, short sellers hold a 16.27% ratio of that float. The average trading volume of SMMT on December 11, 2024 was 4.17M shares.
SMMT’s Market Performance
The stock of Summit Therapeutics Inc (SMMT) has seen a 5.85% increase in the past week, with a -14.42% drop in the past month, and a -32.03% fall in the past quarter. The volatility ratio for the week is 5.92%, and the volatility levels for the past 30 days are at 6.34% for SMMT. The simple moving average for the past 20 days is -0.17% for SMMT’s stock, with a 59.79% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Jefferies, on the other hand, stated in their research note that they expect to see SMMT reach a price target of $31. The rating they have provided for SMMT stocks is “Buy” according to the report published on December 06th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SMMT, setting the target price at $32 in the report published on November 04th of the current year.
SMMT Trading at -5.27% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.03% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares sank -10.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.66% lower at present.
During the last 5 trading sessions, SMMT rose by +5.45%, which changed the moving average for the period of 200-days by +321.82% in comparison to the 20-day moving average, which settled at $18.66. In addition, Summit Therapeutics Inc saw 613.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 54,321 shares at the price of $3.72 back on Mar 27 ’24. After this action, Zanganeh Mahkam now owns 24,923,800 shares of Summit Therapeutics Inc, valued at $201,874 using the latest closing price.
Zanganeh Mahkam, the Chief Executive Officer of Summit Therapeutics Inc, purchase 30,000 shares at $3.75 during a trade that took place back on Mar 26 ’24, which means that Zanganeh Mahkam is holding 30,000 shares at $112,500 based on the most recent closing price.
Stock Fundamentals for SMMT
Current profitability levels for the company are sitting at:
- 772.26 for the present operating margin
- 3.86 for the gross margin
The net margin for Summit Therapeutics Inc stands at 836.93. The total capital return value is set at -0.41. Equity return is now at value -73.22, with -54.54 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -4.61. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -15.68.
Currently, EBITDA for the company is 1.0 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of -57985.44. The receivables turnover for the company is -0.36for trailing twelve months and the total asset turnover is -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.31.
Conclusion
To put it simply, Summit Therapeutics Inc (SMMT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
